European Archives - Page 147 of 1370 - European Medical Journal

Medical Cannabis Improves Sleep and Mood in Patients with Insomnia

Medical cannabis linked to better sleep, mood, and life quality in insomnia patients over 18 months, real-world study finds.

MSD strikes $10bn deal for Verona Pharma

MSD has agreed to acquire UK biopharma company Verona Pharma in a $10bn deal, strengthening its cardio-pulmonary care portfolio.

Do Older Childhood Cancer Survivors Face Higher Health Risks?

Survivors of childhood cancer who live past age 50 face a significantly higher risk of premature death and serious health problems compared with the general population…

Machine Learning Shows Strong Promise in Predicting HIV Risk

Discover how machine learning shows high accuracy for HIV prediction but needs better validation before use in STI clinical practice.

Comparing Treatments for Benign Gastric Outlet Obstruction

Uncovered self-expanding metal stents (SEMS) and balloon dilation are safe and effective treatments for benign gastric outlet obstruction; however, SEMS should not be the first choice due to its associated cost and complications.

Machine Learning Outperforms Self-Care in Acne Treatment Study

Learn how AI-driven skincare improved acne and quality of life more effectively than self-chosen products in recent clinical trial.

Rising STEM stars take home Thermo Fisher Award

A group of 300 middle schoolers are named in the 2025 Thermo Fisher Junior Innovators Challenge for STEM projects in AI to climate change.

Andrew Dunbar

Hema Now: Episode 24: Understanding Myeloproliferative Neoplasms

What are myeloproliferative neoplasms, and what can research reveal about future therapies? Andrew Dunbar explores the biology, resistance, and emerging treatment strategies.

Update to European Treatment Guideline for Large B Cell Lymphomas

A 2025 EHA guideline for managing large B-cell lymphoma includes new recommendations for CAR T-cell therapy in patients who…

How to thrive, and not just survive, at congress

As pharma invests millions in congress presence, the pressure to cut through crowded halls and fleeting interactions has never been higher.